JNJ
$127.74
Johnson & Johnson
$.48
.38%
JNJ
Earnings Whisper ®
N/A
2nd Quarter June 2017
Consensus:  $1.78
Revenue:  $18.99 Bil
Tuesday
Jul 18
6:40 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Tuesday, April 18, 2017

What do you expect when JNJ reports earnings?
Beat
Meet
Miss

Where is JNJ's stock price going from here?
Up
Flat
Down
Stock chart of JNJ
Analysts
Summary of analysts' recommendations for JNJ
Score
Grade
Pivots
Resistance
$128.75
$128.20
$127.73

$127.18

Support
$126.71
$126.16
$125.69
Tweet
Growth
Description
Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin care, oral care, wound care, and women's health fields, nutritional and over-the-counter pharmaceutical products. The company's Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, thrombosis, vaccines, and infectious diseases. Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products; orthopaedic joint reconstruction, spinal care, neurological, and sports medicine products; surgical care, aesthetics, and women's health products. Johnson & Johnson is based in New Brunswick, New Jersey.
Peers
Regeneron PharmaceuticalsBioMarin PharmaceuticalCelgeneEli LillyPfizerVertex PharmaceuticalsBristol-Myers SquibbEndo International plcUltragenyx PharmaceuticalInterCept